Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.51 |
| ▸ | CFD | P00746 | 2/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | INSR | P06213 | 1/20 | 0.34 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1817586 | 0.82 | MTNR1A (0.45) | MTNR1AMTNR1BKDM4E | |
| SCHEMBL652962 | 0.80 | CFD (0.44) | MTNR1AMTNR1BCFDCYP4F2CYP4A11 | |
| SCHEMBL1819235 | 0.80 | MTNR1A (0.46) | MTNR1AMTNR1BCYP4F2CYP4A11 | |
| SCHEMBL25678082 | 0.78 | MTNR1A (0.45) | MTNR1AMTNR1BCYP4F2CYP4A11AKT1 | |
| SCHEMBL7658382 | 0.76 | CFD (0.56) | CFDCYP4F2CYP4A11PTGS1AKT1 | |
| SCHEMBL2249183 | 0.76 | MTNR1A (0.46) | MTNR1AMTNR1BCYP4F2CYP4A11AKT1 | |
| SCHEMBL6044531 | 0.76 | CFD (0.49) | CFDCYP4F2CYP4A11PTGS1KDM4E | |
| SCHEMBL10728499 | 0.72 | CYP4F2 (0.51) | CFDCYP4F2CYP4A11PTGS1AKT1 | |
| SCHEMBL7650416 | 0.72 | PTGS1 (0.66) | CFDCYP4F2CYP4A11PTGS1 | |
| SCHEMBL20734904 | 0.72 | PTGS1 (0.57) | CFDCYP4F2CYP4A11PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1163262-B1 | PHENYLALANINE DERIVATIVES | US GOV HEALTH & HUMAN SERV (US) | 2011-05-11 | — | — | EP | disclosed |
| US-7825216-B2 | Conjugate which inhibits SH2 domains from binding with phosphoproteins for use in prevention and/or treatment of cancer, diabetes, obesity, autoimmune, inflammatory, metabolic and/or cardiovascular diseases; pharmacokinetics, bioavailability | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-11-02 | — | — | US | disclosed |
| US-20070219194-A1 | Conjugate which inhibits SH2 domains from binding with phosphoproteins for use in prevention and/or treatment of cancer, diabetes, obesity, autoimmune, inflammatory, metabolic and/or cardiovascular diseases; pharmacokinetics, bioavailability | GEORGETOWN UNIVERSITY (US) | 2007-09-20 | — | — | US | disclosed |
| US-7226991-B1 | inhibiting SH2 domain binding with a phosphoprotein; to inhibit proliferation of tumor cells; for inhibiting the growth of human breast cancer cells | UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2007-06-05 | — | — | US | disclosed |
| EP-1163262-A1 | PHENYLALANINE DERIVATIVES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY of the DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000056760-A1 | PHENYLALANINE DERIVATIVES | THE UNITED STATES OF AMERICA, REPRESENTED BY SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219194-A1 | Conjugate which inhibits SH2 domains from binding with phosphoproteins for use in prevention and/or treatment of cancer, diabetes, obesity, autoimmune, inflammatory, metabolic and/or cardiovascular diseases; pharmacokinetics, bioavailability | TYRO3, PTMS, ACP1 | MTNR1A 2800/4885MTNR1B 3301/4885CFD 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.